Despite a statistically significant advantage of rivaroxaban over vitamin K antagonists in the prevention of thromboembolism, further discussion is required to address the clinical significance of this finding given the relatively large NNT. With the incidence of major and minor bleeding complications being similar between the therapies, the concern for a higher complication rate with rivaroxaban because of a lack of a proven reversible agent is negligible. Cost is also a key factor when comparing these medications and was addressed in a recent study comparing rivaroxaban and vitamin K antagonistis for patients with nonvalvular atrial fibrillation. The study found that the higher cost of rivaroxaban is offset by the increased cost of initial hospitalization and long-term use of a vitamin K antagonist. Other considerations include diet restrictions, increased dosing complications, and the number of clinical visits for patients receiving a vitamin K antagonist. Considering these factors, rivaroxaban appears to be a reasonable alternative, despite a marginal NNT of 433 to prevent one stroke.
Although this study addressed the key adverse effects of major and minor bleeding disorders, it did not separate or clarify severity of the event, and in particular did not address death rate secondary to these complications.
The original manuscript was published in
Medicine by the Numbers, American Family Physician as part of the partnership between TheNNT.com and AFP.